EUVIMEDEUVIMED entdecken
Crossref

Antagonism of the Platelet-Activating Factor Pathway Mitigates Inflammatory Adverse Events Driven by Anti-erythrocyte Antibody Therapy in Mice

Kevin Doyoon Won iD, Lazaro Gil Gonzalez iD, Yoelys Cruz-Leal, Alequis Pavon Oro iD, Alan H Lazarus iD

The Journal of Immunology · 2024

DOI: 10.4049/jimmunol.2300638 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, 2024. Verfasst von Kevin Doyoon Won und 4 weiteren Autor:innen. Beteiligte Einrichtung: Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Unity Health Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Platelet Activating Factor, Purpura, Thrombocytopenic, Idiopathic, Erythrocytes, Inflammation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Canadian Blood Services (CBS), Canadian Government | Canadian Institutes of Health Research (CIHR).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune thrombocytopenia (ITP) is an autoimmune disease characterized by low platelet counts primarily due to antiplatelet autoantibodies. Anti-D is a donor-derived polyclonal Ab against the rhesus D Ag on erythrocytes used to treat ITP. Unfortunately, adverse inflammatory/hypersensitivity reactions and a Food and Drug Administration–issued black box warning have limited its clinical use. This underscores the imperative to understand the inflammatory pathway associated with anti-erythrocyte Ab-based therapies. TER119 is an erythrocyte-specific Ab with anti-D-like therapeutic activity in murine ITP, while also exhibiting a distinct inflammatory signature involving production of CCL2, CCL5, and CXCL9 but not IFN-γ. Therefore, TER119 has been used to elucidate the potential mechanism underlying the adverse inflammatory activity associated with anti-erythrocyte Ab therapy in murine ITP. Prior work has demonstrated that TER119 administration is associated with a dramatic decrease in body temperature and inflammatory cytokine/chemokine production. The work presented in the current study demonstrates that inhibiting the highly inflammatory platelet-activating factor (PAF) pathway with PAF receptor antagonists prevents TER119-driven changes in body temperature and inhibits the production of the CCL2, CCL5, and CXCL9 inflammatory cytokines in CD-1 mice. Phagocytic cells and a functional TER119 Fc region were found to be necessary for TER119-induced body temperature changes and increases in CXCL9 and CCL2. Taken together, this work reveals the novel requirement of the PAF pathway in causing adverse inflammatory activity associated with anti-erythrocyte Ab therapy in a murine model and provides a strategy of mitigating these potential reactions without altering therapeutic activity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Platelet Activating FactorPurpura, Thrombocytopenic, IdiopathicErythrocytesInflammationPlatelet Membrane GlycoproteinsChemokine CCL2AnimalsMiceChemokine CCL5Chemokine CXCL9Receptors, G-Protein-CoupledSignal TransductionMice, Inbred C57BLAutoantibodiesDisease Models, Animal

Substanzen

Platelet Activating FactorPlatelet Membrane GlycoproteinsChemokine CCL2platelet activating factor receptorChemokine CCL5Chemokine CXCL9Receptors, G-Protein-CoupledCcl5 protein, mouseCcl2 protein, mouseAutoantibodies

Autor:innen und Institutionen

  • Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Unity Health Toronto, Toronto, Ontario, Canada.
  • Department of Medicine and Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
  • Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Innovation and Portfolio Management, Canadian Blood Services, Ottawa, Ontario, Canada.

ORCID-Profile: Kevin Doyoon Won, Lazaro Gil Gonzalez, Alequis Pavon Oro, Alan H Lazarus

Förderung

  • Canadian Blood Services (CBS)
  • Canadian Government | Canadian Institutes of Health Research (CIHR)

Zitieren

APA

Won, K. D., Gil Gonzalez, L., Cruz-Leal, Y., Pavon Oro, A., & Lazarus, A. H. (2024). Antagonism of the Platelet-Activating Factor Pathway Mitigates Inflammatory Adverse Events Driven by Anti-erythrocyte Antibody Therapy in Mice. The Journal of Immunology. https://doi.org/10.4049/jimmunol.2300638

Vancouver

Won KD, Gil Gonzalez L, Cruz-Leal Y, Pavon Oro A, Lazarus AH. Antagonism of the Platelet-Activating Factor Pathway Mitigates Inflammatory Adverse Events Driven by Anti-erythrocyte Antibody Therapy in Mice. The Journal of Immunology. 2024. doi:10.4049/jimmunol.2300638

BibTeX
@article{Won2024,
  author = {Won, Kevin Doyoon and Gil Gonzalez, Lazaro and Cruz-Leal, Yoelys and Pavon Oro, Alequis and Lazarus, Alan H},
  title = {Antagonism of the Platelet-Activating Factor Pathway Mitigates Inflammatory Adverse Events Driven by Anti-erythrocyte Antibody Therapy in Mice},
  journal = {The Journal of Immunology},
  year = {2024},
  doi = {10.4049/jimmunol.2300638}
}
Kostenlos starten →